Aarticle by Francisco Epelde*, Dolores Rexachsorcid, Alvaro Wongorcid and Emilio Luque in Reviews on Recent Clinical Trials, March 23 2026
Clinical trials have long been the backbone of modern medicine. Every pill, injection, or therapy on the pharmacy shelf has passed through years — often decades — of painstaking testing involving thousands of volunteers, massive budgets, and complex regulatory hurdles. But what if some of that work could happen without enrolling a single patient? What if computers could safely test ideas before they ever reach a hospital ward?
A new review published in Reviews on Recent Clinical Trials explores this rapidly emerging possibility. Authored by researchers from Parc Taulí Hospital Universitari and the Universitat Autònoma de Barcelona, the paper examines the promise — and the limits — of Virtual Clinical Trials (VCTs): computer-based simulations that model how drugs and treatments might behave in the human body.
Rather than replacing patients with people in white coats and clipboards, VCTs rely on mathematical models, artificial intelligence, and large datasets to simulate “virtual populations.” These digital patients can represent different ages, biological traits, and disease profiles, allowing researchers to test scenarios that would be slow, expensive, or even unethical to explore in real life.
The appeal is obvious. Traditional clinical trials are among the most expensive steps in drug development, often costing hundreds of millions of dollars and stretching across many years. Late-stage failures are particularly painful — by the time a drug fails in humans, enormous resources have already been spent. Virtual trials offer a way to identify weak candidates earlier, long before real patients are exposed.
But the authors argue that cost savings and speed are only part of the story.
Faster Answers, Lower Risks
One of the most striking advantages of virtual trials is time. While conventional trials unfold over months or years — recruiting patients, monitoring outcomes, analyzing data — a virtual trial can run in hours or days. Researchers can adjust doses, change assumptions, and rerun simulations repeatedly under identical conditions. This repeatability is nearly impossible with human participants.
Such speed can be critical in emergencies. During pandemics or fast-moving public health crises, waiting years for definitive answers can cost lives. Virtual trials offer a way to narrow down promising options quickly, helping guide where real-world testing should focus.
There is also a safety dimension. By exploring potential side effects and treatment failures in silico, researchers can reduce the number of risky or poorly designed human studies. In this sense, virtual trials may strengthen — not weaken — the ethical foundations of clinical research.
The Ethical Questions Beneath the Code
Yet the shift from people to pixels raises profound ethical questions.
At the heart of the debate is trust. Computer models are only as good as the assumptions and data behind them. Human biology is complex, messy, and full of surprises. Critics worry that simulations could miss rare side effects or oversimplify how real patients respond to treatment.
The authors emphasize that virtual trials must never operate in isolation. Their results need to be calibrated and validated against real-world data — from previous clinical trials, medical records, and observational studies. Without this grounding, simulations risk becoming elegant but misleading abstractions.
Another concern is the role of human participants themselves. Traditional trials are not just data-generating exercises; they are lived experiences. Patients volunteer for many reasons: hope, altruism, access to experimental therapies. Removing humans entirely from early research phases could unintentionally distance science from the people it ultimately serves.
The paper argues for balance. Virtual trials should complement — not replace — human studies, especially when it comes to understanding quality of life, lived symptoms, and the social realities of illness.
Equity, Access, and Digital Bias
Proponents often describe virtual trials as “democratizing” research. In theory, simulations can include diverse populations that are historically underrepresented in clinical trials, from older adults to rare genetic subgroups.
But the researchers warn that this promise is conditional. If the data used to build virtual populations are biased or incomplete, those biases will be reproduced — perhaps invisibly — inside the models. Ensuring representativeness requires constant auditing, transparent assumptions, and deliberate inclusion strategies.
In hybrid trial designs, where virtual and real-world elements coexist, digital access also matters. Communities with limited access to technology risk being left behind if safeguards are not built in from the start.
Regulation in a Virtual World
Regulatory oversight is another unresolved frontier. Existing frameworks were designed for trials involving human subjects, hospital sites, and physical monitoring. Virtual trials don’t fit neatly into these categories.
The authors call for updated regulatory standards that evaluate simulations on their transparency, validation, bias controls, and predefined “safety backstops” — clear rules that trigger human testing when uncertainty becomes too great. Ethical review boards, they argue, will need new tools to evaluate not just protocols, but algorithms.
A Tool, Not a Replacement
Ultimately, the paper presents a clear message: virtual clinical trials are not science fiction, nor are they a shortcut around ethical responsibility. Used wisely, they can accelerate early decision-making, reduce unnecessary human risk, and make research more efficient. Used carelessly, they could amplify bias or erode trust.
The future of clinical research, the review suggests, is hybrid. Virtual trials, digital twins, synthetic control arms, and traditional human studies will increasingly work together — each compensating for the others’ limitations.
Medicine has always advanced by adopting new tools. Virtual clinical trials may become one of the most powerful yet — but only if innovation is matched with humility, transparency, and a continued commitment to patient-centered science.
Read the published article here: https://bit.ly/4niMcjt
JOURNAL
Reviews on Recent Clinical Trials
DOI: 10.2174/0115748871436258260114105507
If you want to publish your article please visit : https://bit.ly/4de0DRi
Journal
Reviews on Recent Clinical Trials